Base Dose EBOV GP Vaccine + 2x Base Dose EBOV GP Vaccine + 4x Base Dose EBOV GP Vaccine + 8x Base Dose EBOV GP Vaccine + Placebo + Matrix-M Adjuvant
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout Base Dose EBOV GP Vaccine + 2x Base Dose EBOV GP Vaccine + 4x Base Dose EBOV GP Vaccine + 8x Base Dose EBOV GP Vaccine + Placebo + Matrix-M Adjuvant
Base Dose EBOV GP Vaccine + 2x Base Dose EBOV GP Vaccine + 4x Base Dose EBOV GP Vaccine + 8x Base Dose EBOV GP Vaccine + Placebo + Matrix-M Adjuvant is a phase 1 stage product being developed by Novavax for Ebola. The current trial status is completed. This product is registered under clinical trial identifier NCT02370589. Target conditions include Ebola.
What happened to similar drugs?
2 of 4 similar drugs in Ebola were approved
Approved (2) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
6
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02370589 | Phase 1 | Completed |
Competing Products
20 competing products in Ebola